Advanced Prostate Cancer VL

Nicolas Mottet on EAU Guidelines for patients monitoring under treatment - STOP 6

Details
This video lecture presentations took place at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), in Lisbon, Portugal between in October 2016. The meeting was organised by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal. Nicolas Mottet presents a summary of the 2016 version of the European Association...

Nicolas Mottet on Managing the primary in elderly/unfit patients - STOP 6

Details
Managing the primary in elderly or unfit patients (STOP 6) Biography: Nicolas Mottet, MD, PhD

New Concepts in Androgen Deprivation Therapy (ADT) Agonists vs. Antagonists and All the Rest- Tom Keane

Details
Thomas Keane's video lecture is a state of the art review of personalized androgen deprivation therapy (ADT) for men being treated for advanced prostate cancer. This discussion includes the most recent data and considerations relative to identifying patients with cardiovascular disease, obesity and testosterone, fatty acid synthase (FSH) and adipogenous, high volume metastatic disease, use of doce...

Next-generation sequencing of prostate tumors: Use of individualised biomarkers for prognosis and treatment- Martin Spahn

Details
Next-generation sequencing of prostate tumors: Use of individualised biomarkers for prognosis and treatment (STOP 6) Biography: Martin Spahn, MD

Laurence Klotz on Active surveillance or: Shrinking the gray zone - STOP 6

Details
Active surveillance or Shrinking the gray zone (STOP 6) Biography: Laurence Klotz, MD

Karim Fizazi on Sequencing: Combination or individualized treatment - STOP 6

Details
Sequencing: Combination or individualized treatment (STOP 6) Biography: Karim Fizazi, MD

Karim Fizazi v. Bertrand Tombal on 'Hormone-naive metastatic prostate cancer patients should get chemotherapy and ADT as a standard of care' versus 'ADT and AR pathway-targeted agents still have a rol...

Details
Debate between Karim Fizazi and Bertrand Tombal on 'Hormone-naive metastatic prostate cancer patients should get chemotherapy and ADT as a standard of care' versus 'ADT and AR pathway-targeted agents still have a role in these patients’ (STOP 6) Biographies: Karim Fizazi, MD Bertrand Tombal, MD, PhD , us professor and Chairman, Service d'Urologie, Cliniques universitaires Saint Luc, Université cat...

Mark Emberton on Focal therapy for men with intermediate risk prostate cancer and a solitary lesion should be standard of care - STOP 6

Details
Focal therapy for men with intermediate risk prostate cancer and a solitary lesion should be standard of care (STOP 6) Biography: Mark Emberton, MD, FRCS is a Professor of Interventional Oncology at the University College London. He is an Honorary Consultant Urologist at University College Hospitals NHS Foundation Trust and Founding Pioneer of The Charity Prostate Cancer UK. Dr. Emberton was appoi...

Journal Club: Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormones Agonist and an Antagonist

Details
Thomas Keane provides a journal club review on the article, "Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormones Agonist and an Antagonist", published in the European Association of Urology. The hypothesis and approach for this article includes a discussion around if a GnRH antagonist produce the same risk of cardiovascular complication when compared to an LHRH agonist. Also,...

Journal Club Review: Pharmacokinetic Aspects of the Two Novel Oral Drugs - Charles Ryan

Details
Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide Guillemette E. Benoist, Rianne J. Hendricks, Peter F. A. Mulders, Winald R. Gerritsen, Diederik M. Somford, Jack A. Schalken, Inge M. van Oort, David M. Burger, Nielka P. van Erp In this Journal Club presentation, Dr. Charles Ryan's key points include h...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe